Physician profile
Jessica Mitchell
NPI 1962020115
$2,658.93
in general payments reported to CMS, 2019-2025
15 companies · $543 in 2025
The $543 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $787 · 2023: $684 · 2024: $511 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $816.69 | 2021-2025 | |
| Abbvie INC. | $622.59 | 2022-2025 | |
| Alkermes, INC. | $260.85 | 2022-2025 | Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $259.29 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $187.92 | 2023-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $143.39 | 2022 | |
| Vanda Pharmaceuticals INC. | $131.60 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $51.03 | 2024 | Auvelity |
| Novo Nordisk INC | $46.46 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $34.20 | 2023-2024 | Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $27.59 | 2025 | Qelbree |
| Astellas Pharma US INC | $22.05 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $19.78 | 2022 | |
| Glaxosmithkline, LLC. | $19.41 | 2023 | Shingrix, Bexsero, Pediarix |
| Lilly USA, LLC | $16.08 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.